To the Editor: The recent "New Drugs, Old Drugs" review of low molecular weight heparins (LMWH) and heparinoids1 provides a timely reminder of the limitations of studies that support the use of these agents in preventing venous thromboembolism (VTE), particularly in orthopaedic surgery.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
Correspondence:
- 1. Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002; 177: 379-383. <eMJA full text>
- 2. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
- 3. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 2002; 359: 1715-1720.
- 4. Murray DW, Britton AR, Bulstrode CJK. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br 1996; 78: 863-870.
- 5. Warwick D, Perez J, Vickery C, Bannister G. Does total hip arthroplasty predispose to chronic venous insufficiency? J Arthroplasty 1996; 11: 529-533.
Online responses are no longer available. Please refer to our instructions for authors page for more information.